ArticleEuropean journal of clinical nutrition2025
Glycemic responses of three mango varieties in subjects with and without T2D: a pilot crossover study using OTT and CGM.
Article in European journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesMango consumption is often restricted in diet consumed by people with diabetes due to concerns about its glycemic impact. This study aimed to compare the glycemic effects of mango consumption with those of white bread and glucose in subjects with and without type 2 diabetes (T2D).
methodsWe conducted a two-phase study involving 95 participants (45 with T2D, 50 non-diabetic). Phase 1 employed oral tolerance test (OTT) to assess immediate glycemic responses to mango (Safeda, Dasheri, and Langra), bread, and glucose. Phase 2 utilized continuous glucose monitoring (CGM) to evaluate glycemic profiles over three days.
resultsOn OTT, in non-diabetic subjects, mango consumption resulted in non-significantly lower postprandial glucose peaks compared to glucose and bread, except Langra variety which showed lowest area under the curve for glucose of borderline significance. In subjects with T2D, mango varieties performed similarly to bread. CGM data revealed that mango consumption over three days resulted in a similar glycemic profile to bread in non-diabetic subjects and a lower glycemic profile in subjects with T2D, though most differences were statistically not significant. Mean Amplitude of Glycemic Excursion (MAGE) was significantly lower after mango ingestion as compared to bread in CGM data in subjects with T2D.
conclusionsData show limited glycemic impact of tested mango varieties, comparable to or lower than white bread, especially in T2D subjects. The significant reduction in MAGE observed with mango consumption suggests potential benefits for glycemic variability. With portion control in calorie restrictive diets, mango may be suitable for people with T2D.
Indexed as
Identifiers
40946099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.